» Articles » PMID: 1567459

Staurosporine is a Potent Inhibitor of P34cdc2 and P34cdc2-like Kinases

Overview
Publisher Elsevier
Specialty Biochemistry
Date 1992 Apr 15
PMID 1567459
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

We previously demonstrated that nontransformed cells arrest in the G1 phase of the cell cycle when treated with low concentrations (21 nM) of staurosporine (1). Both normal and transformed cells are blocked in the G2 phase of the cell cycle when treated with higher concentrations (160 nM) of staurosporine (1,2). In the present study, we show that staurosporine inhibits the activity of fractionated p34cdc2 and p34cdc2-like kinases with IC50 values of 4-5 nM. We propose that the G2 phase arrest in the cell cycle caused by staurosporine is due, at least in part, to the inhibition of the p34cdc2 kinases.

Citing Articles

Inducing Exit from Mitosis by Inactivating Cdk1/Cyclin B in Metaphase-Arrested Cells: A Tool to Study Mitotic Exit and Reestablishment of Interphase.

Paulson J Methods Mol Biol. 2024; 2874:183-198.

PMID: 39614056 DOI: 10.1007/978-1-0716-4236-8_15.


Analog-sensitive Cdk1 as a tool to study mitotic exit: protein phosphatase 1 is required downstream from Cdk1 inactivation in budding yeast.

Keaton J, Workman B, Xie L, Paulson J Chromosome Res. 2023; 31(3):27.

PMID: 37690059 DOI: 10.1007/s10577-023-09736-6.


Exit from Mitosis in Budding Yeast: Protein Phosphatase 1 is Required Downstream from Cdk1 Inactivation.

Keaton J, Workman B, Xie L, Paulson J Res Sq. 2023; .

PMID: 37090579 PMC: 10120774. DOI: 10.21203/rs.3.rs-2787001/v1.


Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Peyressatre M, Prevel C, Pellerano M, Morris M Cancers (Basel). 2015; 7(1):179-237.

PMID: 25625291 PMC: 4381256. DOI: 10.3390/cancers7010179.


ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway.

Rajapaksa G, Nikolos F, Bado I, Clarke R, Gustafsson J, Thomas C Oncogene. 2014; 34(31):4130-41.

PMID: 25347741 DOI: 10.1038/onc.2014.343.